Evaluating the safety and efficacy of a polyherbal Unani formulation in dyslipidaemia-a prospective randomized controlled trial

J Ethnopharmacol. 2022 May 10:289:115036. doi: 10.1016/j.jep.2022.115036. Epub 2022 Feb 1.

Abstract

Ethnopharmacological relevance: Unani System of Medicine offers treatment for obesity and dyslipidaemia. Jawarish Falafili (JF) is a Unani polyherbal pharmacopoeial preparation. It has been used in the treatment of obesity for a long time. Dyslipidaemia is a recognised modifiable risk factor for hypertension, ischemic heart disease and stroke. Limitations of the current conventional therapy have provided scope for research of a potential drug in this medical condition. It was hypothesised that JF may ameliorate dyslipidaemia in human participants.

Aim of the study: The main objective of this study was to evaluate the safety and efficacy of the JF.

Materials and methods: This was a prospective randomized, active-controlled, open-label and parallel-group study. We randomized 74 participants of dyslipidaemia into treatment (n = 38) and control (n = 36) groups. Of them, 30 participants in each group completed the trial. The participants of any sex aged between 30 and 60 years, with serum total cholesterol (TC) ≥200 mg/dl and/or serum triglycerides (TG) ≥150 mg/dl and/or low-density lipoprotein cholesterol (LDL-C) level ≥130 mg/dl and/or high-density lipoprotein cholesterol (HDL-C) level <40 mg/dl were enrolled in this study. The participants of the treatment group were treated with JF (10 gm/day) once and atorvastatin (20 mg/day) was given to the control group for 90 days once at night daily.

Results: We observed a significant reduction (treatment group versus control group) in mean serum TC by 22.89% versus 19.36%, TG by 29.90% versus 23.26% and LDL-C by 29.16% versus 27.92% from baseline (p < 0.05). But the change in mean serum HDL-C levels post-treatment was insignificant in both groups (p > 0.05). On intergroup comparison, the magnitude of the difference of mean TC, TG, LDL-C and HDL-C levels between the groups was not statistically significant (p > 0.00.05).

Conclusions: This study concluded that JF and atorvastatin were equally effective in controlling dyslipidaemia. They were tolerated well by all participants and found safe during the course of treatment.

Keywords: Cholesterol; Dyslipidaemia; Jawarish Falafili; Obesity; Unani medicine.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Anticholesteremic Agents / adverse effects
  • Anticholesteremic Agents / isolation & purification
  • Anticholesteremic Agents / pharmacology*
  • Atorvastatin / adverse effects
  • Atorvastatin / pharmacology
  • Dyslipidemias / drug therapy*
  • Female
  • Humans
  • Lipids / blood
  • Male
  • Medicine, Unani / methods*
  • Middle Aged
  • Plant Extracts / adverse effects
  • Plant Extracts / pharmacology*
  • Prospective Studies

Substances

  • Anticholesteremic Agents
  • Lipids
  • Plant Extracts
  • Atorvastatin